Quadrant Capital Group’s Nuvation Bio NUVB Stock Holding History

Quadrant Capital Group’s Portfolio NUVB Stock Details NUVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$12.2K	Hold	2,853	–	–	﹤0.01%	2147
2025 Q4	$25.6K	Hold	2,853	–	–	﹤0.01%	1912
2025 Q3	$10.6K	Buy	+2,853	New	+$7.77K	﹤0.01%	2147
2025 Q2	–	Sell	-1,233	Closed	-$2.17K	–	2172
2025 Q1	$2.17K	Buy	1,233 +765	+163%	+$1.74K	﹤0.01%	2496
2024 Q4	$1.25K	Hold	468	–	–	﹤0.01%	2561
2024 Q3	$1.07K	Hold	468	–	–	﹤0.01%	2586
2024 Q2	$1.37K	Hold	468	–	–	﹤0.01%	2530
2024 Q1	$1.7K	Buy	+468	New	+$899	﹤0.01%	2532
2023 Q1	–	Sell	-1,072	Closed	-$2.06K	–	2766
2022 Q4	$2.06K	Buy	1,072 +480	+81%	+$971	﹤0.01%	2407
2022 Q3	$1K	Buy	+592	New	+$1.69K	﹤0.01%	2540

Other funds holding NUVB

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Quadrant Capital Group's NUVB Position: Q1 2026 in Review

Quadrant Capital Group held its Nuvation Bio (NUVB) position steady in Q1 2026 at 2,853 shares worth $12.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2147.

Quadrant Capital Group first reported a position in NUVB in Q3 2022 and has held it in 10 quarters since. The position peaked at $25.6K in Q4 2025. 231 funds tracked by Wall St. Rank hold NUVB as of Q1 2026.

Quadrant Capital Group held 2,853 shares of Nuvation Bio worth $12.2K as of Q1 2026.
Quadrant Capital Group left its Nuvation Bio share count unchanged in Q1 2026.
Nuvation Bio made up ﹤0.01% of Quadrant Capital Group's portfolio in Q1 2026, its #2147 holding.
Quadrant Capital Group first reported a position in Nuvation Bio in Q3 2022 and has held it in 10 quarters since.
Quadrant Capital Group's Nuvation Bio position peaked at $25.6K in Q4 2025.
231 funds tracked by Wall St. Rank held Nuvation Bio as of Q1 2026.

Based on Quadrant Capital Group's 13F filing for Q1 2026, filed 11 May 2026.